Diagnostic Efficacy of BRAFV600E Immunocytochemistry in Thyroid Aspirates in Bethesda Category IV and Papillary Thyroid Carcinoma

BACKGROUND: In papillary thyroid carcinoma (PTC), BRAFV600E is a common mutation and is associated with aggressive clinical behaviour. Immunocytochemistry (ICC) and molecular testing are recommended in the Bethesda System for Reporting Thyroid Cytopathology 2017 (TBSRTC) category III, IV and V. AIMS...

Descripción completa

Detalles Bibliográficos
Autores principales: Anand, Nidhi, Agrawal, Tushar, Gupta, Anurag, Shukla, Saumya, Pradhan, Roma, Husain, Nuzhat
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8489694/
https://www.ncbi.nlm.nih.gov/pubmed/34703086
http://dx.doi.org/10.4103/JOC.JOC_248_20

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8489694/
https://www.ncbi.nlm.nih.gov/pubmed/34703086
http://dx.doi.org/10.4103/JOC.JOC_248_20

Ejemplares similares